Nuvation Bio Inc.

Company Overview

Business Model: Nuvation Bio Inc. is a global oncology company focused on developing novel and differentiated small molecule therapies to address challenging cancer treatments. The Company leverages extensive expertise in medicinal chemistry, preclinical development, drug development, business development, manufacturing, and commercialization. Its approach involves pursuing oncology targets validated by strong clinical or preclinical data, designing or acquiring best-in-class product candidates to overcome safety liabilities or efficacy limitations of existing drugs, and developing innovative molecules, including drug-drug conjugates. Nuvation Bio Inc. generates revenue through product sales and collaborative licensing agreements.

Market Position: Nuvation Bio Inc. is a commercial-stage oncology company with its lead product, IBTROZI (taletrectinib), approved and commercially launched in the U.S. in June 2025 for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). IBTROZI has also been approved in Japan (commercialized by Nippon Kayaku Co., Ltd under the brand name IBTROZI) and China (commercialized by Innovent Biologics (Suzhou) Co. Ltd. under the brand name DOVBLERON). The Company positions IBTROZI as a potential new standard of care in advanced ROS1+ NSCLC, citing its best-in-class efficacy and safety profile, including high objective response rates, durable responses, prolonged progression-free survival, brain penetrance, and activity against resistance mutations. IBTROZI has received Orphan Drug Designation and Breakthrough Therapy Designations from the U.S. Food and Drug Administration and China’s National Medical Products Administration.

Recent Strategic Developments:

• Commercial Launch: Commercially launched IBTROZI in the U.S. in June 2025 for advanced ROS1+ NSCLC following FDA approval.
• Strategic Acquisition: Completed the acquisition of AnHeart Therapeutics Ltd. on April 9, 2024, which brought taletrectinib and safusidenib into the Company's pipeline.
• International Partnerships: Entered into a license and collaboration agreement with Eisai Co., Ltd. in January 2026 to commercialize taletrectinib in Europe and other territories outside the U.S., China, and Japan. The Company expects to submit a Marketing Authorization Application to the European Medicines Agency in the first half of 2026.
• Pipeline Advancement: Announced positive results from a Phase 2 study of safusidenib in Japanese patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant gliomas in November 2025.
• Financing: Closed a non-dilutive financing of up to $250.0 million from entities affiliated with Sagard Healthcare Partners in March 2025, comprising a $150.0 million synthetic royalty financing and a $100.0 million senior secured term loan. The initial $200.0 million was funded in June 2025.
• Pipeline Prioritization: Discontinued development of NUV-1511, a drug-drug conjugate clinical product candidate, in November 2025 due to inconsistent efficacy.

Geographic Footprint: Nuvation Bio Inc. maintains principal executive offices in New York, New York, and San Francisco, California, with additional office space in Burlington, Massachusetts. Internationally, the Company occupies office space in the People’s Republic of China across Beijing, Guangzhou, Hangzhou, and Shanghai. Commercialization efforts for IBTROZI are active in the U.S., Japan, and China, with planned expansion into Europe and other territories through partnerships.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 98.6%
• Operating Margin: -338.7%
• Net Margin: -325.3%

Investment in Growth (2025):

• R&D Expenditure: $115.1 million (183.0% of revenue)
• Capital Expenditures: $0.4 million (Purchases of property and equipment)
• Strategic Investments: $150.0 million from a synthetic royalty financing and $50.0 million from a senior secured term loan were funded from Sagard Healthcare Partners.

Business Segment Analysis

Nuvation Bio Inc. manages its operations as a single segment focused on oncology development activities.

IBTROZI (Taletrectinib)

Financial Performance (2025):

• Revenue: $62.9 million (comprising $24.7 million in U.S. product revenue and $38.2 million in collaboration and license agreements revenue).
• Growth: U.S. product revenue commenced in June 2025. Collaboration and license agreements revenue increased by $30.3 million (+384.9%) year-over-year.
• Operating Margin: Not directly calculable for this product alone, as costs are not segmented.
• Key Growth Drivers: FDA approval in June 2025 for locally advanced or metastatic ROS1+ NSCLC. Clinical data from TRUST-I and TRUST-II pivotal Phase 2 studies showed confirmed objective response rates (cORR) of 90% in TKI-naïve patients (TRUST-I) and 85% in TKI-naïve patients (TRUST-II). Pooled median duration of response (DOR) matured to 50 months. In TKI-pretreated patients, cORR was 52% (TRUST-I) and 62% (TRUST-II), with median DOR of 13.2 months and 19.4 months, respectively. The product demonstrated brain penetrance, activity against resistance mutations (e.g., G2032R), and a low treatment discontinuation rate (7%).

Product Portfolio: IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Market Dynamics: ROS1+ NSCLC affects approximately 2% of patients with NSCLC, a cancer diagnosed in over one million people globally each year. Up to 35% of newly diagnosed metastatic ROS1+ NSCLC patients have brain metastases, increasing to 55% after initial treatment progression. Partnerships & Clinical Studies:

• U.S. Commercialization: Supported by 71 commercial field team members and 7 medical affairs field team members. Offers Nuvation Connect patient support program.
• Japan: Commercialized by Nippon Kayaku Co., Ltd. under the brand name IBTROZI.
• China: Commercialized by Innovent Biologics (Suzhou) Co. Ltd. under the brand name DOVBLERON.
• Europe & Other Territories: Exclusive license agreement with Eisai Co., Ltd. (January 2026).
• Ongoing Clinical Studies:
  • TRUST-I (China, Phase 2 single-arm pivotal study for ROS1+ NSCLC).
  • TRUST-II (Global, Phase 2 single-arm pivotal study for ROS1+ NSCLC).
  • TRUST-III (China, confirmatory randomized Phase 3 study versus crizotinib for treatment-naïve ROS1+ NSCLC).
  • TRUST-IV (Global, Phase 3 placebo-controlled study for adjuvant treatment of resected ROS1+ early-stage NSCLC).
• In-License Agreement (Daiichi Sankyo Company, Limited): Nuvation Bio Inc. holds exclusive worldwide rights to develop and commercialize taletrectinib. Obligations include up to $20.0 million in commercial sales milestones and high single-digit percentage royalties on worldwide net sales.
• Out-License Agreements:
  • Innovent Biologics (Suzhou) Co. Ltd.: Exclusive rights to commercialize taletrectinib in mainland China, Hong Kong, Macau, and Taiwan. Nuvation Bio China Ltd. has received $67.0 million (upfront, R&D reimbursement, regulatory milestones) and is eligible for up to $17.0 million in additional regulatory milestones, up to $105.0 million in commercial milestones, and tiered royalties (mid-teen to low-twenties) on annual net sales.
  • Nippon Kayaku Co., Ltd.: Exclusive rights to commercialize taletrectinib in Japan. Nuvation Bio Inc. received a $40.0 million upfront payment and $25.0 million upon a regulatory milestone. Eligible for up to $35.0 million in commercial milestones and a lower-mid double-digit percentage royalty on net sales.
  • Eisai Co., Ltd.: Exclusive license to develop and commercialize taletrectinib in the European Union and other specified territories. Nuvation Bio Inc. received a €50 million upfront payment and is eligible for a €25 million regulatory milestone, up to €120 million in sales milestones, and tiered royalties (low- to high-teens) on aggregate annual net sales.

Safusidenib

Financial Performance: Not separately disclosed. Product Portfolio: Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). Market Dynamics: mIDH1 is detected in various tumors, including gliomas, with IDH1R132H being the most common subtype in IDH mutant glioma. The estimated incidence of IDH-mutant glioma in the U.S. is approximately 2,500 new cases per year. Clinical Studies:

• Phase 1 Study (Japan, sponsored by Daiichi Sankyo Company, Limited): Monotherapy in 47 patients. Objective response rates (ORR) were 17.1% for enhancing tumors and 33.3% for non-enhancing tumors. Generally well-tolerated with most adverse events being Grade 1-2.
• Japan Phase 2 Study (Daiichi Sankyo Company, Limited): Open-label, multicenter, single-arm study in 27 patients with IDH1-mutant grade 2 gliomas (no prior anticancer therapy except resection/biopsy). Met primary endpoint with ORR of 44.4%. Median progression-free survival (PFS) not reached at 28 months (87.9% PFS at 24 months).
• SIGMA Study: Ongoing Phase 3 global study evaluating efficacy and safety versus placebo for maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma (target enrollment 300 patients). Also includes a non-pivotal, single-arm cohort for chemotherapy and radiotherapy naïve grade 3 IDH1-mutant oligodendroglioma (approx. 40 patients). In-License Agreement (Daiichi Sankyo Company, Limited): Nuvation Bio Inc. holds exclusive worldwide rights (excluding Japan) to develop and commercialize safusidenib. Obligations include up to $3.0 million in additional development milestones, up to $50.0 million in regulatory milestones, up to $45.0 million in commercial sales milestones, and high single-digit percentage royalties on worldwide net sales.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: Nuvation Bio Inc. has never declared or paid cash dividends and intends to retain all available funds for business development and expansion.
• Dividend Yield: 0%
• Future Capital Return Commitments: None reported.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $164.1 million
• Total Debt: $208.3 million (comprising $5.7 million short-term borrowings, $47.2 million long-term borrowings net of deferred financing costs, and $155.4 million liability related to revenue interest financing agreement).
• Net Cash Position: $(44.2) million (Net Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The $100.0 million senior secured term loan (from Sagard) matures on September 30, 2030, with all outstanding principal due at maturity. Future minimum payments for this loan are $5.1 million in 2026, $5.1 million in 2027, $5.1 million in 2028, $5.1 million in 2029, and $54.0 million in 2030. The revenue interest financing agreement requires tiered royalty payments on U.S. net sales of IBTROZI, ceasing when total payments reach 1.6x, 1.75x, or 2.0x the $150.0 million investment amount by specified dates, or a true-up payment by February 1, 2043, if payments do not reach 1.0x the investment amount.

Cash Flow Generation (2025):

• Operating Cash Flow: $(173.4) million
• Free Cash Flow: $(173.4) million (Operating Cash Flow) - $0.4 million (Capital Expenditures) = $(173.8) million.
• Cash Conversion Metrics: Not explicitly detailed.

Operational Excellence

Production & Service Model: Nuvation Bio Inc. does not own or operate manufacturing facilities and relies entirely on third parties for the manufacture of its investigational products for preclinical and clinical testing, as well as for commercial manufacture of IBTROZI. This strategy aims to maintain an efficient infrastructure, allowing the Company to focus resources on product development. Third parties also handle packaging, labeling, storage, and distribution.

Supply Chain Architecture: The Company obtains taletrectinib active pharmaceutical ingredients (API) and drug product through long-term supply agreements. It currently relies on a single source for taletrectinib API but is developing a second source. For other investigational products, APIs and drug products are sourced from various single-source third-party Contract Manufacturing Organizations (CMOs). The Company is establishing framework agreements with CMOs for necessary quantities on a project-by-project basis and aims to diversify suppliers as warranted.

Key Suppliers & Partners:

• Manufacturing (API & Drug Product): Asymchem, Wuxi STA, Wuxi AppTec (China), Patheon Pharmaceuticals Inc.
• Clinical Research: Contract Research Organizations (CROs), medical institutions, clinical investigators, contract laboratories.
• Distribution: Select network of third-party distributors, specialty pharmacies, and other vendors in the U.S.

Facility Network:

• Principal Executive Offices: New York, New York (7,900 sq ft, lease ends 2027; planning to move to 18,563 sq ft, lease ends 2037 in H2 2026).
• Other U.S. Offices: San Francisco, California (19,418 sq ft, lease ends 2029); Burlington, Massachusetts (2,235 sq ft, lease ends 2027).
• International Offices: People’s Republic of China (Beijing, Guangzhou, Hangzhou, Shanghai; total 1,799 sq meters, leases end 2026-2029).

Operational Metrics: Not explicitly detailed beyond employee headcount.

Market Access & Customer Relationships

Go-to-Market Strategy: For IBTROZI in the U.S., Nuvation Bio Inc. employs a direct sales and marketing infrastructure, including 71 commercial field team members (key account managers and national account teams) and 7 medical affairs field team members. The Company also offers the Nuvation Connect patient support program to assist with access and affordability.

Distribution Channels:

• Direct Sales: Enterprise sales force in the U.S.
• Channel Partners: Relies on a select network of third-party distributors, specialty pharmacies, and other vendors for U.S. distribution.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Not explicitly detailed beyond geographic revenue distribution.

Geographic Revenue Distribution (2025):

• United States: $24.7 million (39.3% of total revenue)
• Japan: $28.8 million (45.8% of total revenue)
• China: $9.4 million (14.9% of total revenue)
• Growth Markets: The Company has partnered with Eisai Co., Ltd. to commercialize taletrectinib in Europe and other territories, indicating a focus on expanding into new international markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. Competition is dynamic, with many large pharmaceutical and biotechnology companies, academic institutions, government agencies, and research organizations actively involved in developing cancer therapies. Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• For IBTROZI (ROS1+ NSCLC):
  • Approved Drugs: Pfizer Inc.’s Xalkori, Roche’s Rozlytrek, and Bristol-Myers Squibb Company’s Augtyro.
  • Clinical-stage: Nuvalent’s zidesamtinib.
• For Safusidenib (mIDH1 glioma):
  • Approved Drugs: Servier’s Voranigo (vorasidenib).
  • Clinical-stage: Rigel’s olutasidenib.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions are constant threats in the rapidly evolving oncology market. The Company's DDC platform is a novel approach, and its success is not yet fully proven, with one DDC candidate (NUV-1511) already discontinued due to inconsistent efficacy.

Competitive Response Strategy: Nuvation Bio Inc. aims to design or acquire novel or best-in-class product candidates that improve activity and overcome the safety liabilities or limitations in efficacy of currently marketed drugs. The Company also focuses on leveraging its deep insights in medicinal chemistry and business development expertise to identify and in-license or acquire additional promising drug candidates.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The Company's near-term prospects are significantly dependent on the successful commercialization of IBTROZI. Market opportunities for IBTROZI may be smaller than estimated, and the product may fail to achieve adequate market acceptance by physicians, patients, and third-party payors.
• Technology Disruption: The Company's DDC platform is unproven, and competing technological approaches could limit the commercial value of its product candidates or render the platform obsolete.
• Customer Concentration: Not explicitly detailed as a specific risk, but general market acceptance is a concern.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Reliance on third parties for manufacturing, including a single source for taletrectinib API, poses risks of production shortages, supply interruptions, and compliance issues with cGMP.
• Geographic Concentration: Operations in China expose the Company to economic, political, regulatory, and trade policy risks.
• Capacity Constraints: The need to scale up production for commercialization and later-stage clinical trials may face challenges with third-party manufacturers.
• Clinical Trial Risks: Clinical trials are expensive, time-consuming, and have uncertain outcomes. Results from earlier studies may not predict future results. Delays in patient enrollment or failure to demonstrate safety and efficacy could significantly impact development timelines and regulatory approvals.
• Companion Diagnostic Development: Reliance on third parties to develop companion diagnostics for targeted therapies like IBTROZI and safusidenib, with potential delays or failures impacting commercial potential.
• Limited Commercial Experience: Limited experience in selling, marketing, and distributing approved drugs, particularly outside the U.S., could hinder commercial success.
• Resource Allocation: Risk of expending limited resources on less profitable or less successful product candidates or indications.
• Employee Misconduct: Exposure to risks of fraudulent conduct or illegal activity by employees, contractors, or collaborators, including non-compliance with regulatory standards.
• Information Technology Systems: Vulnerability to cybersecurity threats, data breaches, and system interruptions, which could lead to regulatory actions, litigation, and reputational harm.

Financial & Regulatory Risks

• Market & Financial Risks: The Company has incurred significant net losses and will require substantial additional funding. Inability to raise capital on favorable terms could delay or terminate development and commercialization efforts. Indebtedness from the Sagard financing imposes debt service obligations and restrictive covenants, potentially limiting financial flexibility and increasing default risk.
• Regulatory & Compliance Risks: Inability to maintain regulatory approval for IBTROZI or other products, including compliance with post-marketing requirements and commitments. Risk of unforeseen side effects post-approval. Health reform measures in the U.S. (e.g., Affordable Care Act, One Big Beautiful Bill Act, Medicare Drug Price Negotiation Program, Loper Bright decision) and the EU (e.g., Pharma Package) could increase costs, reduce reimbursement, or delay approvals. Compliance with federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws (HIPAA, HITECH) is complex and non-compliance could lead to substantial penalties.
• Tax Strategy & Considerations: Changes in tax laws (e.g., OBBBA, BEPS 2.0) could adversely affect the Company's tax profile. Limitations on the use of net operating loss carryforwards and tax credits due to ownership changes (Section 382) could increase future tax liabilities.

Geopolitical & External Risks

• Geopolitical Exposure: International operations, particularly in China, are subject to economic, political, regulatory, and trade risks.
• Trade Relations: U.S.-China trade policies, including tariffs and trade barriers, could increase costs, disrupt supply chains, and impact profitability.
• Sanctions & Export Controls: Compliance with U.S. and foreign export controls and trade sanctions could limit international sales.
• Chinese Regulatory Environment: Compliance with China’s Data Security Law, Cyber Security Law, Personal Information Protection Law, and Human Genetic Resources Regulation entails significant expenses and uncertainties, potentially affecting business operations and data transfer.

Innovation & Technology Leadership

Research & Development Focus: Nuvation Bio Inc.'s R&D strategy is built on pursuing validated oncology targets, leveraging innovative medicinal chemistry expertise, and developing novel small molecules. A key focus is the proprietary Drug-Drug Conjugate (DDC) platform, which aims to create tissue-selective therapies by fusing small molecules to anti-cancer warheads.

Core Technology Areas:

• Small Molecule Oncology: Development of targeted inhibitors like taletrectinib (ROS1 inhibitor) and safusidenib (mIDH1 inhibitor).
• Drug-Drug Conjugate (DDC) Platform: A novel therapeutic approach designed to selectively bind to intracellular and surface cell membrane targets highly expressed in specific tissues, delivering anti-cancer warheads. Key benefits include improved therapeutic index, oral/IV delivery, and potentially simpler manufacturing than antibody-drug conjugates.

Innovation Pipeline:

• Taletrectinib: Approved for ROS1+ NSCLC in the U.S., Japan, and China. Ongoing Phase 3 studies (TRUST-III, TRUST-IV) for advanced and adjuvant early-stage ROS1+ NSCLC.
• Safusidenib: In Phase 3 development (SIGMA study) for maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma, with an exploratory cohort for grade 3 IDH1-mutant oligodendroglioma.
• DDC Platform: Preclinical candidates are being evaluated, though one candidate (NUV-1511) was discontinued due to inconsistent efficacy.

Intellectual Property Portfolio:

• Patent Strategy: Seeks patent protection for compositions of matter, formulations, methods of use, and methods of synthesis for its investigational products in the U.S. and other countries.
• Taletrectinib Patents: Covered by patent families (owned or exclusively licensed from Daiichi Sankyo Company, Limited) expected to expire from 2033 to 2042. A U.S. patent term extension application has been filed, potentially extending a key patent to 2038.
• Safusidenib Patents: Exclusive worldwide (ex-Japan) license from Daiichi Sankyo Company, Limited for patent families expected to expire from 2035 to 2041.
• Trademarks: Nuvation Bio Inc. is a registered trademark. The Company relies on both registered and common law rights for its trademarks.
• Trade Secrets: Relies on trade secrets and confidentiality agreements to protect unpatented know-how and proprietary information.

Technology Partnerships:

• Daiichi Sankyo Company, Limited: Key in-licensing partner for taletrectinib and safusidenib.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company is highly dependent on the management, research and development, clinical, financial, and business development expertise of Dr. Hung and its executive officers. Board Composition: The Board of Directors includes David Hung, M.D. (Chairman), Min Cui, Robert B. Bazemore, Jr. (Lead Independent Director), Kim Blickenstaff, Kathryn E. Falberg, Robert Mashal, M.D., and W. Anthony Vernon. Dual-Class Structure: Nuvation Bio Inc. has a dual-class common stock structure. David Hung, M.D., holds all outstanding shares of Class B Common Stock and approximately 17% of the total Class A and Class B Common Stock. This structure concentrates voting power with Dr. Hung, granting him the right to elect and remove three directors plus at least 50% of any directors in excess of seven, and an approval right over any acquisition or liquidation of the Company.

Human Capital Strategy

Workforce Composition (as of December 31, 2025):

• Total Employees: 298 full-time employees.
• Geographic Distribution: Employees are located across offices in New York, San Francisco, Burlington (MA), and China (Beijing, Guangzhou, Hangzhou, Shanghai).
• Skill Mix: 58 employees hold Ph.Ds, M.Ds, or Pharm.Ds. 147 employees are engaged in research and development, and 151 in selling, general and administrative functions. The Company also utilizes 67 independent contractors.

Talent Management:

• Acquisition & Retention: The Company prioritizes attracting, motivating, and retaining talent at all levels, recognizing employees as significant assets. It offers competitive compensation and comprehensive benefits packages.
• Employee Value Proposition: Fosters a productive, professional, and inclusive work environment, aiming to inspire exceptional contributions and professional/personal development. Equity and cash incentive plans are used to attract, retain, and reward personnel.

Diversity & Development:

• Diversity Metrics: The workforce comprises approximately 58% female employees and approximately 34% racial/ethnic minority employees.
• Development Programs: Committed to providing a culture that supports employee growth and career advancement.

Regulatory Environment & Compliance

Regulatory Framework: Nuvation Bio Inc. operates under extensive regulatory frameworks in the U.S. (FDA, FDCA, PDUFA, Hatch-Waxman Act), Japan (MHLW), China (NMPA), and is preparing for regulatory submissions in the EU (EMA) and UK (MHRA). The Company utilizes expedited development and review programs such as Orphan Drug Designation, Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval. Industry-Specific Regulations:

• Healthcare Fraud and Abuse Laws: Subject to federal and state anti-kickback statutes, false claims laws (including the False Claims Act), HIPAA (privacy and security of health information), and the Physician Payments Sunshine Act, as well as comparable foreign healthcare laws.
• Companion Diagnostics: The development and commercialization of companion diagnostics are subject to FDA approval/clearance as medical devices in the U.S. and to the IVDR in the European Economic Area, requiring CE mark conformity assessment.
• International Compliance: Compliance with diverse and evolving laws, regulations, and court systems across multiple jurisdictions, including those related to data privacy and security (e.g., EU GDPR, UK GDPR, China's Data Security Law, Cyber Security Law, Personal Information Protection Law, Human Genetic Resources Regulation).

Trade & Export Controls: The Company's global supply chain and international operations are subject to U.S. and foreign export controls, trade sanctions, and import laws and regulations. Changes in international trade policies, particularly between the U.S. and China, including tariffs and trade barriers, can significantly impact costs and supply chain stability.

Legal Proceedings: On July 30, 2025, a derivative complaint was filed against the Company's directors alleging excessive compensation, which was voluntarily discontinued without prejudice on November 12, 2025.

Tax Strategy & Considerations

Tax Profile (as of December 31, 2025):

• Effective Tax Rate: 0% (due to full valuation allowance).
• Net Operating Loss (NOL) Carryforwards: $330.6 million federal (unlimited carryover period, subject to 80% taxable income limitation), $440.5 million state (begin to expire in 2038).
• Research and Development Tax Credits: $18.6 million federal (begin to expire in 2039), $3.4 million state (unlimited carryover period).
• Orphan Drug Tax Credits: $11.3 million federal (begin to expire in 2042).
• Valuation Allowance: A full valuation allowance is maintained against all net deferred tax assets due to a history of cumulative losses and expected future U.S. losses.
• Unrecognized Tax Benefits: $10.1 million as of December 31, 2025.

Tax Reform Impact:

• One Big Beautiful Bill Act (OBBBA) (July 2025): Restores tax deductibility of domestic R&D expenses in the year incurred (effective after Dec 31, 2024), modifies international tax framework, and permanently extends certain Tax Cuts and Jobs Act provisions.
• BEPS 2.0 (Pillar Two): The Company is monitoring global proposals for a minimum effective corporate tax rate but currently expects to be outside its scope based on revenue thresholds.
• Section 382 Limitations: The Company's ability to use pre-change NOL carryforwards and tax attributes may be limited due to prior ownership changes (e.g., AnHeart acquisition).

Geographic Tax Planning: Chinese regulations (e.g., SAFE Circular 37 for offshore special purpose companies, SAT Circular 7 for indirect transfers of equity interests) may impact capital injection into Chinese subsidiaries and tax treatment of certain transactions.

Insurance & Risk Transfer

Risk Management Framework: Nuvation Bio Inc. maintains product liability insurance, workers’ compensation insurance, and public liability insurance to cover potential liabilities arising from its research, development, manufacturing, marketing, and use of pharmaceutical products. The Company assesses and manages cybersecurity risks through various processes, including automated tools, threat intelligence services, internal/external audits, and a dedicated cybersecurity staff, with oversight from the audit committee of the board of directors.